Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $5.7MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Nicolas Leupin | Officer | Jul 23 '26 | Proposed Sale | $15.57 | 39,088 | $608,600 | — | Jul 23 04:21 PM |
| Leonard Frank X | Chief Executive Officer | Jun 04 '26 | Sale | $17.93 | 34,273 | $614,635 | 459,520 | Jun 05 04:28 PM |
| Francis Leonard | Officer | Jun 04 '26 | Proposed Sale | $17.93 | 34,273 | $614,635 | — | Jun 04 05:41 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.